Literature DB >> 6459784

Human postthymic precursor cells in health and disease. IV. Abnormalities in immunoregulatory T cell circuits in mixed connective tissue disease.

D Alarcón-Segovia, R Palacios.   

Abstract

Human T cells are capable of forming rosettes with autologous erythrocytes (Tar cells) and behave as postthymic precursors. Thus, they generate Tgamma and Tmu cells as well as suppression and spontaneous cytotoxicity and participate in a pokeweed mitogen-driven system akin to that of feedback inhibition in which murine postthymic precursors participate. Tar cells were increased in 7 patients with mixed connective tissue disease (MCTD) compared to normal age/sex-matched controls. Despite this increase of precursor cells, decreased Tgamma cells and abrogation in the generation of suppression and of feedback inhibition were noted. These functional defects were not correctable with serum thymic factor but could be corrected by the addition of either allogenic Tmu or mononuclear cells depleted of Tar cells. Our findings suggest that the immunoregulatory T cell circuits in MCTD may be adequate both in postthymic precursor cells and in the thymic factor prompting. They are probably abnormal either at the site of Tmu signaling to Tar cells in feedback inhibition or in the Tmu reception of suppressor signals from Tgamma cells. The decrease of Tgamma cells in MCTD could be due to the decreased stimulus from feedback inhibition and/or to the penetration of anti-ribonucleoprotein antibody. Abnormalities of immunoregulatory T cell circuits in MCTD are quite different from those found previously in systemic lupus erythematosus, scleroderma, and rheumatoid arthritis. These differences support the notion that MCTD is a distinct entity.

Entities:  

Mesh:

Year:  1981        PMID: 6459784     DOI: 10.1002/art.1780241206

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  8 in total

1.  A defect in immunoregulatory synovial fluid T cells in Behçet's syndrome.

Authors:  J Alcocer-Varela; A Laffon; C Abud-Mendoza; D Alarcon-Segovia
Journal:  Clin Rheumatol       Date:  1989-03       Impact factor: 2.980

2.  Circulating lupus type anticoagulant and pulmonary hypertension associated with mixed connective tissue disease.

Authors:  P Hainaut; E Lavenne; J M Magy; E G Lebacq
Journal:  Clin Rheumatol       Date:  1986-01       Impact factor: 2.980

3.  Mixed connective tissue disease: some statements.

Authors:  D Alarcón-Segovia
Journal:  Clin Rheumatol       Date:  1982-06       Impact factor: 2.980

4.  The B-cell activation pathway in human systemic lupus erythematosus: imbalanced in vitro production of lymphokines and association with serum analytical findings.

Authors:  M L Gaspar; M Alvarez-Mon; C Gutierrez
Journal:  J Clin Immunol       Date:  1988-07       Impact factor: 8.317

5.  Cellular regulation of anti-nRNP antibody synthesis is different from that of anti-DNA antibody synthesis in patients with systemic lupus erythematosus.

Authors:  O Hosono; T Takeuchi; J Koide; M Takano; T Abe
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

6.  Differences in the kinetics of the autologous mixed lymphocyte reaction between the various connective tissue diseases.

Authors:  A Laffón; J Alcocer-Varela; D Alarcón-Segovia
Journal:  Rheumatol Int       Date:  1983       Impact factor: 2.631

7.  Natural killer cell-mediated activity in mixed connective tissue disease and its response to induction by interleukin-2.

Authors:  R González-Amaro; J Alcocer-Varela; E Martínez-Cordero; D Alarcón-Segovia
Journal:  J Clin Immunol       Date:  1984-07       Impact factor: 8.317

8.  Differences in the production of and/or the response to interleukin-2 by T lymphocytes from patients with the various connective tissue diseases.

Authors:  J Alcocer-Varela; A Laffón; D Alarcón-Segovia
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.